title: Hepatic metastases from gastric cancer: A surgical perspective.
abstract: Management of patients with hepatic metastases as the sole metastatic site at diagnosis of gastric cancer (synchronous setting) or detected during follow-up (metachronous) is controversial. The prevailing attitude in these cases is passive, leading to surgical palliation and, possibly, to chemotherapy. Authors focused this editorial in order to promote a more pragmatic attitude. They stress the importance of recognizing the good candidates to curative surgery of both gastric cancer and hepatic metastases (synchronous setting) or hepatic disease alone (metachronous disease) from those who will not benefit from surgical therapy. In fact, in adequately selected subgroup of patients surgery, especially if integrated in multimodal therapeutic strategies, may achieve unexpected 5-year survival rates, ranging from 10% to 40%. The critical revision of the literature suggests that some simple clinical criteria exist that may be effectively employed in patients selection. These are mainly related to the gastric cancer (factors T, N, G) and to the extent of hepatic involvement (factor H). Upon these criteria it is possible to adequately select about 50% of cases. In the remaining 50% of cases a critical discussion on a case-by-case basis is recommended, considering that among these patients some potential long-survivors exist, that survival is strictly influenced by the ablation of the tumor bulk and by multimodality treatments including chemotherapy and that in expert institutions this kind of surgery is performed with very low mortality and morbidity rates.
authors.affiliation: Guido Alberto Massimo Tiberio, Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia, 25100 Brescia, Italy.
authors.forename: Guido Alberto Massimo
authors.initials: GA
authors.lastname: Tiberio
authors.affiliation: Guido Alberto Massimo Tiberio, Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia, 25100 Brescia, Italy.
authors.forename: Franco
authors.initials: F
authors.lastname: Roviello
authors.affiliation: Guido Alberto Massimo Tiberio, Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia, 25100 Brescia, Italy.
authors.forename: Annibale
authors.initials: A
authors.lastname: Donini
authors.affiliation: Guido Alberto Massimo Tiberio, Surgical Clinic, Department of Clinical and Experimental Sciences, University of Brescia, 25100 Brescia, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: de Manzoni
mesh_terms: D017024:Chemotherapy, Adjuvant; D005743:Gastrectomy / Q000009:adverse effects; D006498:Hepatectomy / Q000009:adverse effects; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary* / Q000601:surgery*; D020360:Neoadjuvant Therapy; D018579:Patient Selection; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000473:pathology* / Q000601:surgery*; D016896:Treatment Outcome
keywords: Chemotherapy; Gastrectomy; Gastric cancer; Hepatectomy; Hepatic metastases; Selection criteria; Surgical palliation; Therapeutic strategy